Borik Rita M, Hussein Mohammed Abdalla
Department of Chemistry, Faculty of Science (Female Section), Jazan University, Jazan 82621, Saudi Arabia.
Department of Biochemistry, Faculty of Applied Medical Sciences, October 6 University, Sixth of October City, Egypt.
Curr Pharm Biotechnol. 2022;23(9):1179-1203. doi: 10.2174/1389201022666210601170650.
Quinazolines are a common class of nitrogen-containing heterocyclic scaffolds, which exhibit a broad spectrum of pharmacological activities.
In the present study, quinazoline and quinazolin-4-one derivatives were prepared, characterized, and evaluated for their biological activity, which may pave the way for possible therapeutic applications.
New derivatives of quinazoline and quinazolin-4-one were prepared and tested for antiulcerogenic, anti-inflammatory and hepatoprotective activities.
The synthesized compounds were characterized by elemental analysis and spectral data. Also, the median lethal doses (LD50s) of compounds 1-3 in rats were 1125, 835 and 1785 mg/kg b.w., respectively. IC50 values of compounds (1-3) as measured by ABTS•+ radical method were 0.8, 0.92 and 0.08 mg/mL, respectively. Antiulcerogenic activity at dose 1/20 LD50 in albino rats was observed at 47.94, 24.60 and 56.45%, respectively. Anti-inflammatory effect at dose 1/20 LD50 of compounds (1-3) was observed in the induced edema model after 120 min. The prepared compounds were found to possess hepato gastric mucosa protective activity against ibuprofen-induced ulceration and LPS-induced liver toxicity, respectively, in rats etc. normalization of oxidative stress biomarkers, and inflammatory mediators were inhibited in peritoneal macrophage cells at a concentration of 100 μg/L. Molecular docking suggested that the most active compounds 1 and 2 could be positioned within the active sites of COX-2 at Arg121 and Tyr356, similarly to ibuprofen (Arg-120, Glu-524, and Tyr-355). The compound 3-COX-2 complex generated by docking revealed intricate interactions with a COX-2 channel.
These findings suggest that compounds 1-3 exhibited good antioxidant, antiulcer, and anti-inflammatory activities, and were safe on liver enzymes in rats.
喹唑啉是一类常见的含氮杂环骨架,具有广泛的药理活性。
在本研究中,制备、表征了喹唑啉和喹唑啉-4-酮衍生物,并对其生物活性进行了评估,这可能为潜在的治疗应用铺平道路。
制备了喹唑啉和喹唑啉-4-酮的新衍生物,并测试了它们的抗溃疡、抗炎和保肝活性。
通过元素分析和光谱数据对合成的化合物进行了表征。此外,化合物1-3在大鼠中的半数致死剂量(LD50)分别为1125、835和1785mg/kg体重。用ABTS•+自由基法测得化合物(1-3)的IC50值分别为0.8、0.92和0.08mg/mL。在白化大鼠中,以1/20 LD50剂量给药时,观察到的抗溃疡活性分别为47.94%、24.60%和56.45%。在诱导水肿模型中,在120分钟后观察到化合物(1-3)以1/20 LD50剂量给药的抗炎作用。发现所制备的化合物分别对大鼠布洛芬诱导的溃疡和脂多糖诱导的肝毒性具有胃黏膜保护活性等。氧化应激生物标志物的正常化以及炎症介质在腹膜巨噬细胞中以100μg/L的浓度被抑制。分子对接表明,活性最强的化合物1和2可以与布洛芬(Arg-120、Glu-524和Tyr-355)类似地定位在COX-2的Arg121和Tyr356活性位点内。对接产生的化合物3-COX-2复合物显示出与COX-2通道的复杂相互作用。
这些发现表明化合物1-3表现出良好的抗氧化、抗溃疡和抗炎活性,并且对大鼠肝脏酶是安全的。